Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) shares were up 2.1% on Monday . The company traded as high as $3.47 and last traded at $2.90. Approximately 279,718 shares traded hands during trading, a decline of 44% from the average daily volume of 496,017 shares. The stock had previously closed at $2.84.
A number of research analysts have recently commented on SNNA shares. Cowen set a $45.00 price target on shares of Sienna Biopharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 3rd. BMO Capital Markets cut their price target on shares of Sienna Biopharmaceuticals from $27.00 to $17.00 and set an “outperform” rating on the stock in a report on Tuesday, December 4th. Zacks Investment Research upgraded shares of Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Wednesday, December 19th. Finally, ValuEngine cut shares of Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 24th.
The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $60.04 million, a P/E ratio of -0.57 and a beta of 3.72.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.03). As a group, equities analysts forecast that Sienna Biopharmaceuticals Inc will post -3.49 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of SNNA. Bank of New York Mellon Corp grew its holdings in Sienna Biopharmaceuticals by 15.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 36,945 shares of the company’s stock worth $561,000 after acquiring an additional 4,956 shares in the last quarter. BlackRock Inc. grew its holdings in Sienna Biopharmaceuticals by 10.6% during the 2nd quarter. BlackRock Inc. now owns 1,010,338 shares of the company’s stock worth $15,348,000 after acquiring an additional 97,162 shares in the last quarter. Northern Trust Corp grew its holdings in Sienna Biopharmaceuticals by 17.7% during the 2nd quarter. Northern Trust Corp now owns 147,584 shares of the company’s stock worth $2,242,000 after acquiring an additional 22,146 shares in the last quarter. Creative Planning bought a new position in Sienna Biopharmaceuticals during the 3rd quarter worth about $263,000. Finally, Assenagon Asset Management S.A. bought a new position in Sienna Biopharmaceuticals during the 3rd quarter worth about $1,653,000. Institutional investors own 45.77% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was reported by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://macondaily.com/2019/02/11/sienna-biopharmaceuticals-snna-trading-up-2-1.html.
About Sienna Biopharmaceuticals (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.